Drug Discovery, Drug Research Editorial
-
Drugging The Undruggable: Strategies And Future Directions
3/7/2024
Progress with PROTACs and molecular glues hasn’t come without challenges, particularly in identifying the right chemistry starting point for drug development — a process known as hit discovery. This article looks at the role of CRISPR, screening assays, and more.
-
8 Key Takeaways Of The Proposed FDA Modernization Act 3.0
3/6/2024
On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview. Note that the proposed legislation would still need to go through its course of passing the House and Senate and being signed by the president before becoming a law.
-
Is WuXi AppTec An Enemy Of The State?
2/20/2024
I have zero sympathies for the Chinese communist regime. My stance on tariffs and other economic and market-access blocking measures to combat the regime is more ambivalent. But is WuXi AppTec an enemy combatant against the citizens of the U.S., as proposed legislation assumes?
-
Why Are Cell-Therapy Outsourcers Unhappy? Investors Know
2/19/2024
Some private research indicates cell-therapy sponsors aren't happy with outsourcing options. In this part two with a successful investor, we find out how that sentiment might change for the better.
-
PROTACs And Molecular Glues: Rethinking What Is Possible
2/9/2024
This article explores the potential of novel small molecule approaches to address undruggable targets in oncology, including PROteolysis TArgeting Chimeras (PROTACs) and molecular glues, and how they work.
-
A Future Renaissance At Catalent? Employees Think So
2/8/2024
Re Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief Editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with.
-
Beyond (And Better Than) mRNA: T Cell Vaccines
2/1/2024
During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.
-
Creating T Cell Vaccines In The Sands
1/25/2024
Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”
-
Vaccine Manufacture From The U.K. to Brazil And Saudi Arabia
1/22/2024
Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.
-
Understanding Undruggable Targets: Challenges And Progress
1/18/2024
As we continue to discover new treatment approaches, we need to go beyond targeting proteins with well-defined pockets and find other ways to target the undruggable. Two approaches that show promise are PROTACs and molecular glues.